Avenue Therapeutics Submits New Drug Application for IV Tramadol
Avenue Therapeutics (NASDAQ: ATXI), a subsidiary of Fortress Biotech Inc, announced the submission of a New Drug Application (NDA) to the FDA, for IV tramadol, an intravenous solution intended for the treatment of moderate to moderately severe pain in adults. The Company is focused on...
